title: Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
abstract: From 1997 to 2003, 40 patients (all <40 years of age) with non-metastatic osteosarcoma of the extremities were treated with OOS-D and definitive surgery. Two cycles of doxorubicin 90 mg/m(2) plus cisplatin 120 mg/m(2) and ifosfamide 15 g/m(2) were given  as neoadjuvant chemotherapy, and two cycles of doxorubicin/cisplatin and ifosfamide, and two cycles of high-dose methotrexate (10-12 g/m(2)) were given post-operatively. All patients underwent limb salvage surgeries, and 66% showed good response to neoadjuvant chemotherapy.  With a median follow-up period of 117 months, 31 of the evaluable 40 patients were continuously disease-free, 7 were currently alive with no evidence of disease, and 2 died of disease. There was no local recurrence. The 5-year event-free and overall survival rates were 83 and 98%, respectively.  The 10-year event-free and overall survival rates were 80 and 95%, respectively. The major form of toxicity was haematological one.
authors: Osaka National Hospital, Osaka, Japan. kudawara@onh.go.jp
authors: Ikuo
authors: I
authors: Kudawara
authors: Yasuaki
authors: Y
authors: Aoki
authors: Takafumi
authors: T
authors: Ueda
authors: Nobuhito
authors: N
authors: Araki
authors: Norifumi
authors: N
authors: Naka
authors: Hirofumi
authors: H
authors: Nakanishi
authors: Akihiko
authors: A
authors: Matsumine
authors: Makoto
authors: M
authors: Ieguchi
authors: Shigeki
authors: S
authors: Mori
authors: Akira
authors: A
authors: Myoui
authors: Shigeyuki
authors: S
authors: Kuratsu
authors: Nobuyuki
authors: N
authors: Hashimoto
authors: Hideki
authors: H
authors: Yoshikawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005121:Extremities / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007223:Infant; D007231:Infant, Newborn; D007564:Japan; D023821:Limb Salvage / Q000379:methods; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate